Accéder au contenu
Merck
Toutes les photos(1)

Documents

P2670000

Praziquantel

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H24N2O2
Numéro CAS:
55268-74-1
Poids moléculaire :
312.41
Numéro Beilstein :
761557
Numéro MDL:
MFCD00058531
Code UNSPSC :
41116107
ID de substance PubChem :
329820147
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

praziquantel

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

Clé InChI

FSVJFNAIGNNGKK-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Praziquantel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001533

Praziquantel, European Pharmacopoeia (EP) Reference Standard

1554658

Composé A apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

1554603

Praziquantel, United States Pharmacopeia (USP) Reference Standard

1554669

Composé B apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

1554670

Composé C apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

PHR2961

(11bRS)-2-Benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, pharmaceutical secondary standard, certified reference material

PHR2962

2-(Cyclohexylcarbonyl)-2,3,6,7-tétrahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, pharmaceutical secondary standard, certified reference material

PHR2963

2-(N-Formylhexahydrohippuroyl)-1,2,3,4-tétrahydroisoquinoline-1-one, pharmaceutical secondary standard, certified reference material

Mentions de danger

H412

Conseils de prudence

P273

Classification des risques

Aquatic Chronic 3

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
M J Doenhoff et al.
Parasitology, 136(13), 1825-1835 (2009-03-14)
Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. Attention
Wei Wang et al.
Parasitology research, 111(5), 1871-1877 (2012-10-12)
Since praziquantel was developed in 1970s, it has replaced other antischistosomal drugs to become the only drug of choice for treatment of human schistosomiases, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost.
Jennifer Keiser et al.
PLoS neglected tropical diseases, 8(7), e2975-e2975 (2014-07-18)
Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, which calls for
Michael J Doenhoff et al.
Current opinion in infectious diseases, 21(6), 659-667 (2008-11-04)
Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale. This review focuses on current knowledge about the mechanisms of action of PZQ, prospects for PZQ resistance, possible future alternative drugs and on exhortations
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique